bioAffinity Tech Financials

BIAF

Key Financial Metrics

Revenue

$9.4M

YoY+269.7%

bioAffinity Tech generated $9.4M in revenue in fiscal year 2024. This represents an increase of 269.7% from the prior year.

EBITDA

-$8.3M

YoY-8.1%

bioAffinity Tech's EBITDA was -$8.3M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 8.1% from the prior year.

Free Cash Flow

-$7.3M

YoY-21.2%

bioAffinity Tech generated -$7.3M in free cash flow in fiscal year 2024, representing cash available after capital expenditures. This represents a decrease of 21.2% from the prior year.

Net Income

-$9.0M

YoY-13.9%

bioAffinity Tech reported -$9.0M in net income in fiscal year 2024. This represents a decrease of 13.9% from the prior year.

EPS (Diluted)

$-0.75

YoY+17.6%

bioAffinity Tech earned $-0.75 per diluted share in fiscal year 2024. This represents an increase of 17.6% from the prior year.

Cash & Debt

$1.1M

YoY-60.8%

bioAffinity Tech held $1.1M in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

507,520

YoY-94.6%

bioAffinity Tech had 507,520 shares outstanding in fiscal year 2024. This represents a decrease of 94.6% from the prior year.

Gross Margin

N/A

Operating Margin

-95.6%

YoY+219.2pp

bioAffinity Tech's operating margin was -95.6% in fiscal year 2024, reflecting core business profitability. This is up 219.2 percentage points from the prior year.

Net Margin

-96.6%

YoY+216.8pp

bioAffinity Tech's net profit margin was -96.6% in fiscal year 2024, showing the share of revenue converted to profit. This is up 216.8 percentage points from the prior year.

Return on Equity

N/A

R&D Spending

$1.5M

YoY-0.5%

bioAffinity Tech invested $1.5M in research and development in fiscal year 2024. This represents a decrease of 0.5% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$79K

YoY+245.3%

bioAffinity Tech invested $79K in capital expenditures in fiscal year 2024, funding long-term assets and infrastructure. This represents an increase of 245.3% from the prior year.

BIAF Income Statement

Metric	FY24	FY24	FY23	FY22
Revenue	$9.4M+269.7%	$2.5M+52627.4%	$5K	N/A
Cost of Revenue	N/A	N/A	$467	N/A
Gross Profit	N/A	N/A	$4K	N/A
R&D Expenses	$1.5M-0.5%	$1.5M+6.5%	$1.4M+36.8%	$1.0M
SG&A Expenses	$9.9M+46.4%	$6.8M+173.7%	$2.5M+132.1%	$1.1M
Operating Income	-$9.0M-12.3%	-$8.0M-98.8%	-$4.0M-81.8%	-$2.2M
Interest Expense	$92K+149.1%	$37K-98.5%	$2.5M+152.8%	$1.0M
Income Tax	$12K-44.5%	$21K+753.7%	$2K+26.1%	$2K
Net Income	-$9.0M-13.9%	-$7.9M+2.7%	-$8.2M-28.9%	-$6.3M
EPS (Diluted)	$-0.75+17.6%	$-0.91+49.7%	$-1.81	N/A

Metric	Q3'25	Q2'25	Q1'25	Q3'25	Q3'25	Q2'25	Q1'25	Q4'24
Revenue	$1.4M+13.9%	$1.3M-31.5%	$1.9M	N/A	$2.4M-2.0%	$2.4M-0.4%	$2.4M	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$331K+6.2%	$311K-15.2%	$367K	N/A	$274K-31.8%	$402K+2.2%	$394K	N/A
SG&A Expenses	$2.2M-0.2%	$2.2M-9.7%	$2.5M	N/A	$2.4M-4.4%	$2.5M+13.1%	$2.2M	N/A
Operating Income	-$2.3M+8.9%	-$2.5M+4.2%	-$2.6M	N/A	-$2.0M+5.5%	-$2.1M-7.3%	-$1.9M	N/A
Interest Expense	$5K-48.8%	$10K-32.5%	$15K	N/A	$22K-2.8%	$22K-5.5%	$24K	N/A
Income Tax	$3K-89.0%	$29K+233.3%	$9K	N/A	$3K-52.8%	$5K+47.6%	$4K	N/A
Net Income	-$5.1M-24.4%	-$4.1M-52.6%	-$2.7M	N/A	-$2.0M+5.2%	-$2.1M-7.6%	-$2.0M	N/A
EPS (Diluted)	$-4.74-2688.2%	$-0.17-6.3%	$-0.16	N/A	$-4.84-2447.4%	$-0.19+5.0%	$-0.20	N/A

BIAF Balance Sheet

Metric	FY24	FY24	FY23	FY22
Total Assets	$6.5M-20.8%	$8.2M-32.5%	$12.2M+738.2%	$1.5M
Current Assets	$2.7M-32.2%	$4.0M-66.8%	$12.0M+731.7%	$1.4M
Cash & Equivalents	$1.1M-60.8%	$2.8M-75.3%	$11.4M+738.9%	$1.4M
Inventory	$28K+49.4%	$18K+233.6%	$6K	N/A
Accounts Receivable	N/A	N/A	N/A	N/A
Goodwill	$1.4M0.0%	$1.4M	N/A	N/A
Total Liabilities	$3.9M+16.2%	$3.4M+195.6%	$1.1M-93.4%	$17.2M
Current Liabilities	$3.1M+38.1%	$2.2M+97.4%	$1.1M-91.3%	$13.0M
Long-Term Debt	N/A	N/A	N/A	N/A
Total Equity	$2.6M-46.4%	$4.9M-56.0%	$11.0M+169.9%	-$15.8M
Retained Earnings	-$53.6M-20.3%	-$44.6M-21.6%	-$36.7M-28.6%	-$28.5M

Metric	Q3'25	Q2'25	Q1'25	Q3'25	Q3'25	Q2'25	Q1'25	Q4'24
Total Assets	$11.5M+143.0%	$4.8M-14.4%	$5.5M-14.8%	$6.5M-0.6%	$6.6M-1.6%	$6.7M-17.3%	$8.0M-2.1%	$8.2M
Current Assets	$8.6M+416.1%	$1.7M-10.5%	$1.9M-30.8%	$2.7M+5.7%	$2.5M-4.9%	$2.7M-31.8%	$3.9M-1.0%	$4.0M
Cash & Equivalents	$7.7M+855.3%	$803K-75.3%	$3.3M+194.0%	$1.1M+46.1%	$757K-5.6%	$801K-67.3%	$2.5M-13.1%	$2.8M
Inventory	$35K-19.9%	$44K+13.4%	$39K+40.5%	$28K+8.9%	$25K-14.8%	$30K+213.8%	$9K-48.7%	$18K
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	$1.4M0.0%	$1.4M0.0%	$1.4M0.0%	$1.4M0.0%	$1.4M0.0%	$1.4M0.0%	$1.4M0.0%	$1.4M
Total Liabilities	$2.6M-61.6%	$6.9M+67.7%	$4.1M+5.0%	$3.9M+14.0%	$3.4M+6.4%	$3.2M+15.4%	$2.8M-17.1%	$3.4M
Current Liabilities	$2.4M-8.8%	$2.6M-24.2%	$3.4M+10.0%	$3.1M+24.6%	$2.5M+7.1%	$2.3M+31.3%	$1.8M-21.2%	$2.2M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$8.9M+516.7%	-$2.1M-248.4%	$1.4M-44.7%	$2.6M-16.6%	$3.1M-9.1%	$3.4M-34.7%	$5.3M+8.3%	$4.9M
Retained Earnings	-$65.4M-8.4%	-$60.4M-7.2%	-$56.3M-5.0%	-$53.6M-5.9%	-$50.7M-4.1%	-$48.7M-4.5%	-$46.6M-4.4%	-$44.6M

BIAF Cash Flow Statement

Metric	FY24	FY24	FY23	FY22
Operating Cash Flow	-$7.3M-20.3%	-$6.0M-48.3%	-$4.1M-98.7%	-$2.0M
Capital Expenditures	$79K+245.3%	$23K-89.6%	$220K	N/A
Free Cash Flow	-$7.3M-21.2%	-$6.1M-41.2%	-$4.3M	N/A
Investing Cash Flow	-$79K+96.4%	-$2.2M-904.3%	-$220K	N/A
Financing Cash Flow	$5.6M+1731.3%	-$345K-102.4%	$14.3M+331.2%	$3.3M
Dividends Paid	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q3'25	Q3'25	Q2'25	Q1'25	Q4'24
Operating Cash Flow	N/A	N/A	-$1.6M	N/A	N/A	N/A	-$2.3M	N/A
Capital Expenditures	N/A	N/A	$51K	N/A	N/A	N/A	$41K	N/A
Free Cash Flow	N/A	N/A	-$1.7M	N/A	N/A	N/A	-$2.4M	N/A
Investing Cash Flow	N/A	N/A	-$51K	N/A	N/A	N/A	-$41K	N/A
Financing Cash Flow	N/A	N/A	$1.0M	N/A	N/A	N/A	$2.0M	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

BIAF Financial Ratios

Metric	FY24	FY24	FY23	FY22
Gross Margin	N/A	N/A	90.3%	N/A
Operating Margin	-95.6%+219.2pp	-314.8%+83196.7pp	-83511.5%	N/A
Net Margin	-96.6%+216.8pp	-313.4%+169457.8pp	-169771.3%	N/A
Return on Equity	N/A	N/A	N/A	N/A
Return on Assets	-138.8%-42.2pp	-96.5%-29.6pp	-66.9%+368.4pp	-435.3%
Current Ratio	0.87-0.9	1.77-8.7	10.50+10.4	0.11
Debt-to-Equity	1.50+0.8	0.69+0.6	0.10+1.2	-1.09
FCF Margin	-78.4%+160.9pp	-239.3%+89097.2pp	-89336.5%	N/A

Metric	Q3'25	Q2'25	Q1'25	Q3'25	Q3'25	Q2'25	Q1'25	Q4'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-158.6%+39.6pp	-198.2%-56.4pp	-141.7%	N/A	-84.0%+3.1pp	-87.1%-6.2pp	-80.8%	N/A
Net Margin	-349.3%-29.4pp	-319.9%-176.3pp	-143.5%	N/A	-85.1%+2.9pp	-88.0%-6.5pp	-81.5%	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-43.8%+41.7pp	-85.5%-37.5pp	-48.0%	N/A	-30.5%+1.2pp	-31.7%-7.3pp	-24.4%	N/A
Current Ratio	3.65+3.0	0.64+0.1	0.55-0.3	0.87-0.2	1.02-0.1	1.15-1.1	2.22+0.5	1.77
Debt-to-Equity	0.30+3.5	-3.22-6.1	2.85+1.4	1.50+0.4	1.10+0.2	0.94+0.4	0.53-0.2	0.69
FCF Margin	N/A	N/A	-91.3%	N/A	N/A	N/A	-99.2%	N/A

Frequently Asked Questions

What is bioAffinity Tech's annual revenue?

bioAffinity Tech (BIAF) reported $9.4M in revenue for fiscal year 2024.

How fast is bioAffinity Tech's revenue growing?

bioAffinity Tech (BIAF) revenue grew by 269.7% year-over-year, from $2.5M to $9.4M in fiscal year 2024.

Is bioAffinity Tech profitable?

No, bioAffinity Tech (BIAF) reported a net income of -$9.0M in fiscal year 2024, with a net profit margin of -96.6%.

What is bioAffinity Tech's earnings per share (EPS)?

bioAffinity Tech (BIAF) reported diluted earnings per share of $-0.75 for fiscal year 2024.

What is bioAffinity Tech's EBITDA?

bioAffinity Tech (BIAF) had EBITDA of -$8.3M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

What is bioAffinity Tech's operating margin?

bioAffinity Tech (BIAF) had an operating margin of -95.6% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.

What is bioAffinity Tech's net profit margin?

bioAffinity Tech (BIAF) had a net profit margin of -96.6% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.

What is bioAffinity Tech's free cash flow?

bioAffinity Tech (BIAF) generated -$7.3M in free cash flow during fiscal year 2024, representing cash available after capital expenditures.

What is bioAffinity Tech's operating cash flow?

bioAffinity Tech (BIAF) generated -$7.3M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are bioAffinity Tech's total assets?

bioAffinity Tech (BIAF) had $6.5M in total assets as of fiscal year 2024, including both current and long-term assets.

What are bioAffinity Tech's capital expenditures?

bioAffinity Tech (BIAF) invested $79K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.

How much does bioAffinity Tech spend on research and development?

bioAffinity Tech (BIAF) invested $1.5M in research and development during fiscal year 2024.

How many shares does bioAffinity Tech have outstanding?

bioAffinity Tech (BIAF) had 507,520 shares outstanding as of fiscal year 2024.

What is bioAffinity Tech's current ratio?

bioAffinity Tech (BIAF) had a current ratio of 0.87 as of fiscal year 2024, which is below 1.0, which may suggest potential liquidity concerns.

What is bioAffinity Tech's debt-to-equity ratio?

bioAffinity Tech (BIAF) had a debt-to-equity ratio of 1.50 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is bioAffinity Tech's return on assets (ROA)?

bioAffinity Tech (BIAF) had a return on assets of -138.8% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.